Compare Unilever plc (UL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs Zimmer Biomet Holdings Inc — how do they compare? Unilever plc trades at $62.03 (market cap $136.96B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Unilever plc is far larger — about 7.6× Zimmer Biomet Holdings Inc's market cap, and Unilever plc pays the higher dividend (3.34%). Which is the better fit depends on your goals.
| UL | ZBH | |
|---|---|---|
Market Cap | $136.96B | $17.97B |
Sector | Consumer Staples | Health |
52-Week High | $74.59 | $104.26 |
52-Week Low | $55.05 | $79.58 |
Enterprise Value | $162.94B | $25.04B |
Dividend Yield | 3.34% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $63.54, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings misses contrast with strong profitability, including a net income margin of 18.32% and ROE of 54.57% for 2025. The company reported its strongest quarterly volume growth in over a decade in Q2 2026, raising its full-year outlook, while strategic shifts include focusing on beauty and personal care and a planned $65 billion merger with McCormick.
The outlook is mixed: robust fundamentals and strategic refocusing support long-term growth, particularly in emerging markets, but consistent earnings misses and a high P/E ratio of 21.46 pose valuation concerns. Risks include integration challenges from the McCormick deal and competitive pressures. Analyst consensus is divided, with 24% buy ratings, highlighting cautious optimism amid execution uncertainties.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
